Post-earnings recap
Reported
Wed, Jul 29, 2026
EPS actual
$0.02
EPS est.
$0.05
EPS surprise
-60.00%
1-day move
+9.60%
Teva Pharmaceutical's earnings report shows a significant miss on EPS, which typically raises concerns among investors. However, the stock reacted positively, increasing by 9.6%. This could indicate that investors are looking beyond the earnings miss, possibly due to other factors not captured in the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.02 | $0.70 | -60.00% |
| Revenue | — | $4.2B | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Teva Pharmaceutical Industries Limited is a global leader in the pharmaceutical industry, specializing in generic and specialty medicines. With a market cap of $43 billion, Teva plays a crucial role in providing affordable healthcare solutions, especially in a time when healthcare costs are a major concern for consumers and governments alike.
Last quarter
In Q1-2026, Teva reported an EPS of $0.53, exceeding expectations by 8.83%. The stock reacted positively, gaining 11.89% the following day.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
88%
Avg EPS surprise
+6.79%
Avg 1-day reaction
+4.22%
Analysts expect Teva to report solid earnings this quarter, with a consensus EPS of $0.70 and revenue of $4.2 billion. The market is closely watching for any signs of growth in its specialty drug segment.
Bull case
If Teva beats earnings estimates, it could signal strong demand for its products and effective cost management, potentially leading to a stock price increase.
Bear case
On the other hand, if Teva misses expectations, it may raise concerns about its growth prospects and competitive position in the pharmaceutical market.
Key metrics to watch
EPS
$0.70Earnings per share is a key indicator of profitability, and this quarter's estimate reflects market expectations for Teva's financial performance.
Revenue
$4.2BRevenue figures provide insight into the company's sales performance and market demand for its products, which is critical for assessing growth.
The print will turn on these.
Q1
Will Teva's EPS exceed the consensus estimate of $0.70?
A beat on EPS would reinforce confidence in Teva's profitability and operational effectiveness, potentially boosting the stock.
Q2
What are the revenue figures for Teva's specialty drug segment?
Growth in this area is critical for Teva's long-term strategy and could indicate its ability to compete effectively in the market.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.5%
Why consensus could be wrong
The consensus may underestimate Teva's ability to leverage its generic drug portfolio, which could drive higher revenue growth than expected.
Supporting evidence
Teva's recent history of beating EPS estimates suggests stronger operational performance.
The company's commitment to expanding its specialty drug offerings could lead to unexpected revenue boosts.
Options pricing indicates lower volatility than historical averages, suggesting the market may not fully account for potential upside.
Key risk
If specialty drug revenue shows significant growth, it could challenge current market expectations.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will indicate whether Teva can maintain its growth trajectory amidst a competitive landscape.
Bull confirmed if
An EPS of $0.74 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $0.60 would raise concerns about profitability and market competitiveness.
What the market is pricing for the move.
Implied Move
±5.66%
Historical Avg
±9.5%
The options market is pricing in a move of about 5.66%, suggesting that investors are anticipating some volatility around the earnings report.
Options are pricing ±5.7% while TEVA has averaged ±9.5% over the last 8 prints — setup is pricing cheap.
ATM IV
0.4%
30d HV
39.9%
Smart-money positioning from the most recent 13F filings.
Institutional
26.37%
of float
Insider
0.56%
of float
Holders
119
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
63,894,301 sh · $2.5B
5.48%
-1.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Teva beats estimates, history suggests the stock could rise by about 3.79%, confirming a positive outlook for the company.
In line / cautious
If results are in line, the stock may see muted movement as investors await further guidance from management.
Miss
A miss could lead to a decline, with historical patterns indicating an average drop of around 3.79%.
The lines on the call that would change the story.
Harel Insurance Investments & Financial Services Ltd.
48,138,805 sh · $1.9B
4.13%
4.8%
Phoenix Financial Ltd.
42,933,367 sh · $1.7B
3.68%
0.4%
WCM Investment Management, LLC
41,315,232 sh · $1.6B
3.55%
1.2%
Clal Insurance Enterprises Holdings Ltd
40,596,506 sh · $1.6B
3.48%
5.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.